Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis
(RA) but the balance of benefit and harm is still unclear. Methods The GLORIA …

To develop recommendations for the management of medium to high-dose (ie,> 7.5 mg
but≤ 100 mg prednisone equivalent daily) systemic glucocorticoid (GC) therapy in …

Objectives: This report reviews the clinical effectiveness and cost-effectiveness of
adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-a (TNF-a) …

Introduction Infection is a major cause of morbidity and mortality in patients with rheumatoid
arthritis (RA). The objective of this study was to perform a systematic review and meta …

Objective. Comorbidities such as cardiovascular diseases (CVD), cancer, osteoporosis, and
depression are often underrecognized in patients with rheumatoid arthritis (RA), psoriatic …

Glucocorticoids (GCs) rapidly reduce disease activity in early and advanced rheumatoid
arthritis (RA). This systematic review on behalf of the task force on recommendations for the …

Glucocorticoids are widely used anti-inflammatory and immunosuppressive drugs for
rheumatoid arthritis (RA). The disease-modifying potential of low to medium doses of …

Objectives To assess the risk of new-onset or worsening hyperglycaemia, hypertension,
weight gain and hyperlipidaemia with systemic corticosteroid therapy (CST) as reported in …